Antiviral drugs

Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Health sciences, Health care, Antiviral drugs, Orphan drugs, Brincidofovir, Ebola, Prodrugs, Biopharmaceutical, Glioma

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m.

Key Points: 
  • DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m.
  • Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and an efficacy analysis by blinded independent central review is expected later in 2021.

FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)

Retrieved on: 
Friday, July 30, 2021
Health sciences, Articles, Health, Antiviral drugs, COVID-19 drug development, Monoclonal antibodies, Casirivimab/imdevimab, Roche, COVID-19, Regeneron Pharmaceuticals

REGEN-COV is not a substitute for vaccination against COVID-19, and is not authorized for pre-exposure prophylaxis to prevent COVID-19.

Key Points: 
  • REGEN-COV is not a substitute for vaccination against COVID-19, and is not authorized for pre-exposure prophylaxis to prevent COVID-19.
  • This authorization enables these groups to use REGEN-COV to prevent infection in post-exposure and certain institutional settings.
  • REGEN-COV has not been approved by the FDA, but is currently authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under section 564(b)(1) of the Act, 21 U.S.C.
  • Consequently, REGEN-COV remains available for use across the U.S., and Regeneron will continue actively monitoring the potency of REGEN-COV against emerging variants.

Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021
Drugs, Antiviral drugs, Brincidofovir, Ebola, Prodrugs, Infectious diseases, Medical specialties, Smallpox

ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

Key Points: 
  • ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.
  • A live audio webcast of the call will also be available on the Investors section of the Company's website, www.chimerix.com .
  • An archived webcast will be available on the Chimerix website approximately two hours after the event.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.

GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

Retrieved on: 
Wednesday, July 28, 2021
Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Antiviral drugs, COVID-19 drug development, Pharmacy, Food and Drug Administration, United States Public Health Service, Biologics license application, Sotrovimab, Biopharmaceutical

The Joint Procurement Agreement enables participating European Union (EU) Member States to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.

Key Points: 
  • The Joint Procurement Agreement enables participating European Union (EU) Member States to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.
  • GSK and Vir have secured supply agreements with multiple governments around the world and will continue those efforts as the pandemic continues to evolve.
  • GSK and Vir have announced plans to submit a Biologics License Application (BLA) to the U.S. FDA in the second half of 2021.
  • GSK and Vir are committed to ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve at different rates across the globe and new variants of concern and interest emerge.

Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment

Retrieved on: 
Friday, July 23, 2021
Antiviral drugs, Medical specialties, Health, Zoonoses, GC376, COVID-19, Virus, Protease inhibitor, Vaccine, Rupintrivir, 3CLpro-1

While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.

Key Points: 
  • While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.
  • GC376 is a protease inhibitor, designed to block the replication process and stop the virus from spreading.
  • GC376 has the potential to be a One Health medicine, providing therapeutic benefits to both pets and people.
  • Anivive has filed a pre-Investigational New Drug request with the Food and Drug Administration to evaluate GC376 as a post-infection treatment of COVID-19 in humans.

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim

Retrieved on: 
Thursday, July 22, 2021
3C-like protease, Sarbecovirus, Protease inhibitor, Protease, Antiviral drugs

The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim.

Key Points: 
  • The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim.
  • The Company intends to establish a monthly subscription model as part of its marketing launch campaign for Tollovid Daily immune system support.
  • Tollovid and Tollovid Daily are both 3CL protease inhibitor products developed under a joint venture with NLC Pharma.
  • We are very excited with the new FDA Certificate of Free Sale for Tollovid Daily, the newest member of our Tollovid dietary supplement product line, said Gerald E. Commissiong, President & CEO of Todos Medical.

Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Medicine, Infectious diseases, Zoonoses, Antiviral drugs, Viruses, Alphavirus, Togaviruses, Coronavirus, Bunyavirales, Equine encephalitis, Rift Valley fever

New antiviral data included Brilacidins inhibition of SARS-CoV-2 in additional cell lines (Caco-2, primary lung fibroblasts), and Brilacidins inhibition of alphavirusesVenezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virusand Rift Valley Fever Virus, a bunyavirus.

Key Points: 
  • New antiviral data included Brilacidins inhibition of SARS-CoV-2 in additional cell lines (Caco-2, primary lung fibroblasts), and Brilacidins inhibition of alphavirusesVenezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virusand Rift Valley Fever Virus, a bunyavirus.
  • Our scientific team looks forward to exploring Brilacidin further as we investigate the breadth of its antiviral profile.
  • Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidins potential to be developed as a broad-spectrum antiviral.
  • A peer-reviewed article in Viruses supporting Brilacidins COVID-19 treatment potential can be accessed at the link below.

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Zoonoses, Animal diseases, Sarbecovirus, Antiviral drugs, Human coronavirus 229E, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Coronavir, COVID-19, Middle East respiratory syndrome–related coronavirus, Severe acute respiratory syndrome coronavirus

The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.

Key Points: 
  • The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.
  • Further, in vitro studies have shown that zotatifin has potent antiviral activity across all unique coronavirus subtypes tested, including SARS-CoV-2, SARS-CoV-1, MERS-CoV and CoV-229E.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, has recently completed the dose-escalation portion of a Phase 1/2 trial, and is now progressing into Phase 2a indication-specific expansion cohorts.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Medicine, Health, Sarbecovirus, Zoonoses, Antiviral drugs, Biocides, 3C-like protease, Masitinib, Severe acute respiratory syndrome coronavirus 2, Broad-spectrum antiviral drug, COVID-19

This direct-acting antiviral mechanism of action distinguishes masitinib from many other COVID-19 drugs, including polymerase inhibitors or monoclonal antibodies.

Key Points: 
  • This direct-acting antiviral mechanism of action distinguishes masitinib from many other COVID-19 drugs, including polymerase inhibitors or monoclonal antibodies.
  • Also reported for the first time are data on the effectiveness of masitinib as an anti-SARS-CoV-2 drug in animals.
  • Remarkably, masitinib was also effective, in vitro, against all tested variants of concern, including the rapidly spreading Alpha, Beta and Gamma variants.
  • Thus, masitinib is a relatively broad-spectrum antiviral with potential activity against multiple viruses that rely on 3CL protease to complete their life cycle.

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Coronaviridae, Zoonoses, Variants of SARS-CoV-2, Antiviral drugs, COVID-19 pandemic in Russia, Severe acute respiratory syndrome coronavirus 2, COVID-19, SARS-CoV-2 Delta variant, Immunome, Coronavir

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.
  • Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
  • IMM-BCP-01s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19.
  • Currently, the delta variant accounts for a majority of coronavirus cases in the United States.